Genetically engineered mice have become the """"""""gold standard"""""""" for animal models in cancer. They are widely used to mimic human cancers with specific point mutations in tumor suppressor genes, as well as tissuespecific expression of mutations in somatic tissues. By combining several mutations in one animal, it is now possible to phenocopy human cancers that were difficult to reproduce previously in animal models. The Genetically Engineered Mouse Facility (GEMF) provides valuable resources to Cancer Center members. It generates transgenic and gene-targeted mice, performs embryo rederivations to generate pathogen-free mice, and provides cryopreservation services to archive animal models. The Mouse Resource Facility (MRF), as part of the GEMF, provides vectors for construct development, northern blots of adult and embryonic tissues, genomic DNA and cDNA libraries, and BAG filter sets. The MRF also has a small colony of Cre and lacZ transgenic mice essential for generating conditional deletions in mice. The GEMF thus provides unique opportunities to faculty to develop sophisticated animal models to study a variety of cancer problems. The GEMF has been extremely successful in generating and maintaining mouse models. In the last five years, the GEMF has generated animal models for more than 300 projects for MDACC investigators and has cryopreserved more than 120 mouse lines. A >1000% increase has been achieved in utilization of mouse resources through the MRF. The lead facility coordinator has developed new, more efficient methods of generating embryos for use by the facility. She is responsible for training faculty and their staff, and provides genetic and technical expertise to many investigators in many different programs. In addition to the facility coordinator, the GEMF is staffed by 7 highly-trained technicians. In the past five years, the GEMF has served 96 different users who represent 19 of the 20 sponsored programs;97% of the investigators served are MDACC faculty. To better serve the needs of our investigators and add needed capacity, a small satellite facility was added recently to the South Campus. This expansion will enable the GEMF to develop more models and offer additional services. The GEMF is currently funded from multiple sources, including 53% provided by the CCSG and 45% recovered through user fees, with the remainder provided by MDACC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-37S2
Application #
8530377
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$2,882
Indirect Cost
$1,058
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Yao; Hu, Hao; Chen, Jiun-Sheng et al. (2018) Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes. Biochim Biophys Acta Mol Basis Dis 1864:2247-2254
Melancon, Marites P; Appleton Figueira, Tomas; Fuentes, David T et al. (2018) Development of an Electroporation and Nanoparticle-based Therapeutic Platform for Bone Metastases. Radiology 286:149-157
Zhao, Hui; Zhang, Ning; Ho, Vivian et al. (2018) Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124:679-687
Pan, Hubert Y; Jiang, Jing; Hoffman, Karen E et al. (2018) Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol 36:1823-1830
Grossberg, Aaron J; Mohamed, Abdallah S R; Elhalawani, Hesham et al. (2018) Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data 5:180173
Lu, Zhimin; Hunter, Tony (2018) Metabolic Kinases Moonlighting as Protein Kinases. Trends Biochem Sci 43:301-310
Beadnell, Thomas C; Nassar, Kelsey W; Rose, Madison M et al. (2018) Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis 7:23
Chen, Xiuhui; Mangala, Lingegowda S; Rodriguez-Aguayo, Cristian et al. (2018) RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37:107-124
Kono, Miho; Fujii, Takeo; Matsuda, Naoko et al. (2018) Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. J Cancer 9:3640-3646
Khouri, Issa F; Fernandez Curbelo, Irina; Turturro, Francesco et al. (2018) Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 24:1011-1018

Showing the most recent 10 out of 12418 publications